SCHEMBL24700138

SCHEMBL24700138

CC1C(c2ccccc2)CCCN1C(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 1/20 0.52
▸ HCRTR2 O43614 1/20 0.48
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ RORC P51449 1/20 0.46
▸ GPR119 Q8TDV5 1/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ UCHL1 P09936 2/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ KLK7 P49862 1/20 0.44
▸ LMNA P02545 2/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ CNR2 P34972 1/20 0.42
▸ NR1H2 P55055 2/20 0.42
▸ NR1H3 Q13133 2/20 0.42
▸ KDM1A O60341 1/20 0.42
▸ MAOB P27338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4247938 0.92 RORC (0.47) RIPK1HCRTR2RORCGPR119NR1H2
SCHEMBL4247942 0.92 RORC (0.47) RIPK1HCRTR2RORCGPR119NR1H2
SCHEMBL4247946 0.92 RORC (0.47) RIPK1HCRTR2RORCGPR119NR1H2
SCHEMBL829779 0.86 RIPK1 (0.51) RIPK1HCRTR2MEN1KMT2ARORC
SCHEMBL829709 0.86 RIPK1 (0.51) RIPK1HCRTR2MEN1KMT2ARORC
SCHEMBL829778 0.86 RIPK1 (0.51) RIPK1HCRTR2MEN1KMT2ARORC
SCHEMBL829414 0.85 RIPK1 (0.53) RIPK1HCRTR2MEN1KMT2ARORC
SCHEMBL829416 0.85 RIPK1 (0.53) RIPK1HCRTR2MEN1KMT2ARORC
SCHEMBL829415 0.85 RIPK1 (0.53) RIPK1HCRTR2MEN1KMT2ARORC
SCHEMBL18642714 0.83 RIPK1 (0.69) RIPK1HCRTR2MEN1KMT2AGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220380314-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-01 — — US disclosed
US-20220380314-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-01 — — US disclosed
CN-114901652-A Substituted saturated and unsaturated N-heterocyclic carboxamides and related compounds for the treatment of medical disorders 比亚尔R&D投资股份公司 2022-08-12 — — CN disclosed
EP-4031540-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Bial-R&D Investments, S.A. (PT) 2022-07-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380314-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GBA2, CLN6 RIPK1 2840/4885HCRTR2 665/4885MEN1 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback